SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

XRAY

DENTSPLY SIRONA Inc.
BEARISH
Impact 6/10
Horizonweeks Processed11d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor Q4 2026 results for execution on the Return-to-Growth Action Plan, particularly whether the Wellspect Healthcare momentum broadens to other segments and if operating cash flow recovers from the Q3 trough.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.46
T+0 close · Nov 5, 2026 · via day close
Latest settled
−3.17%
T+5 · $9.16 · next T+20 in 20d
Vs SPY
−5.77%
α at T+5
Latest observation
−4.56%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $9.46entry
  2. T+1 · 8d ago +0.85%α −1.52% · $9.54
  3. T+5 · 4d ago −3.17%α −5.77% · $9.16
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dentsply Sirona reported Q3 2026 adjusted EPS of $0.29, missing the $0.31 consensus, on net sales of $836M, below the $861.7M consensus. Revenue declined 7.6% YoY (7.0% constant currency), with all segments except Wellspect Healthcare (up 10.1%) contracting. The company lowered its FY2026 outlook to approximately $3.5B in net sales and adjusted EPS of $1.20-$1.30.

Key Financial Metrics

EPS (Adj.)
$0.29
est $0.31 · -6.5% · GAAP: $-0.01
Revenue
$836.0M
est $861.7M · -3.0% · -7.6% YoY
Rating
miss
Guidance
approximately $3.5 billion
lowered
Free Cash Flow
$0.00
Gross Margin
52.9%

Key Facts

  • Q3 2026 net sales $836M, down 7.6% YoY from $904M
  • Q3 2026 adjusted EPS $0.29, down 29.4% YoY from $0.42
  • GAAP diluted loss per share ($0.01) vs ($2.14) in Q3 2025
  • Adjusted EBITDA $146M, down 13.3% YoY; margin 17.3% vs 18.4%
  • Wellspect Healthcare segment grew 10.1% as-reported; all other segments declined
  • FY2026 outlook lowered to ~$3.5B net sales and adjusted EPS $1.20-$1.30
  • Operating cash flow $32M vs $79M in Q3 2025; free cash flow $0M vs $40M
  • Company repurchased 1.2M shares for ~$13M in Q3

Financial Impact

Revenue miss of ~$25.7M vs consensus; adjusted EPS miss of $0.02 vs consensus; FY guidance lowered to $1.20-$1.30 adjusted EPS

revenueepsoperating cash flowfree cash flow

Segment Breakdown

SegmentRevenueGrowth
Connected Technology Solutions$230.0M-11.0%
Essential Dental Solutions$343.0M-4.0%
Orthodontic and Implant Solutions$171.0M-16.6%
Wellspect Healthcare$92.0M+10.1%

Risk Factors

  • Continued revenue decline in core segments (Connected Technology Solutions -11%, Orthodontic and Implant Solutions -16.6%)
  • Operating cash flow deterioration and free cash flow at zero in Q3
  • FY2026 guidance implies a weak Q4 to hit the $1.20-$1.30 adjusted EPS range

Market Snapshot

Exchange
Nasdaq
Sector
Dental Equipment & Supplies
Analyst Consensus
35% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396986

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026